(BAX) Baxter International - Ratings and Ratios
IV Solutions, Infusion Devices, Injectable Drugs, Surgical Sealants, Dialysis Equipment
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 35.3% |
| Value at Risk 5%th | 47.6% |
| Relative Tail Risk | -17.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.29 |
| Alpha | -57.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.684 |
| Beta | 0.862 |
| Beta Downside | 1.062 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.61% |
| Mean DD | 33.50% |
| Median DD | 32.74% |
Description: BAX Baxter International October 30, 2025
Baxter International Inc. (NYSE:BAX) is a diversified healthcare-product company headquartered in Deerfield, Illinois. It serves U.S. and global markets through three operating segments-Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals-offering a broad array of items such as sterile IV solutions, infusion devices, parenteral nutrition, generic injectables, surgical hemostats, smart-bed systems, patient-monitoring tools, and respiratory health equipment. Sales channels include a direct force, independent distributors, drug wholesalers, and specialty pharmacies, and the firm operates in North America, Europe, Asia, the Middle East, Africa, and Latin America.
Key recent metrics underscore Baxter’s scale and financial health: FY 2023 revenue reached approximately $12.5 billion, with operating cash flow of about $2.2 billion and an adjusted EPS of $4.55. The company’s acquisition of Hill-Rom in 2021 expanded its smart-hospital-bed portfolio, positioning it to capture growth in the hospital-capital-expenditure cycle, which the American Hospital Association estimates will rise 3-4 % annually through 2027. Additionally, the home-infusion market-driven by an aging population and increasing preference for outpatient care-is projected to grow at a CAGR of roughly 6 % over the next five years, a segment where Baxter’s specialty injectable and compounding services are well-aligned.
For a deeper quantitative assessment of BAX’s valuation metrics and peer comparisons, the ValueRay platform offers a concise dashboard worth reviewing.
BAX Stock Overview
| Market Cap in USD | 9,613m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1981-10-27 |
| Return 12m vs S&P 500 | -51.2% |
| Analyst Rating | 3.44 of 5 |
BAX Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.90% |
| Yield on Cost 5y | 1.00% |
| Yield CAGR 5y | 1.76% |
| Payout Consistency | 55.9% |
| Payout Ratio | 21.6% |
BAX Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -30.64% |
| CAGR/Max DD Calmar Ratio | -0.46 |
| CAGR/Mean DD Pain Ratio | -0.91 |
| Current Volume | 8297.5k |
| Average Volume | 8297.5k |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-341.0m TTM) > 0 and > 6% of Revenue (6% = 661.4m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -2.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.65% (prev 22.64%; Δ 6.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 488.0m > Net Income -341.0m (YES >=105%, WARN >=100%) |
| Net Debt (7.99b) to EBITDA (1.03b) ratio: 7.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (514.0m) change vs 12m ago 0.39% (target <= -2.0% for YES) |
| Gross Margin 35.39% (prev 38.21%; Δ -2.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 46.18% (prev 44.11%; Δ 2.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.13 (EBITDA TTM 1.03b / Interest Expense TTM 311.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.18
| (A) 0.15 = (Total Current Assets 6.93b - Total Current Liabilities 3.77b) / Total Assets 21.07b |
| (B) 0.70 = Retained Earnings (Balance) 14.84b / Total Assets 21.07b |
| (C) 0.00 = EBIT TTM 41.0m / Avg Total Assets 23.87b |
| (D) 0.85 = Book Value of Equity 11.79b / Total Liabilities 13.85b |
| Total Rating: 4.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.71
| 1. Piotroski 1.50pt |
| 2. FCF Yield -0.13% |
| 3. FCF Margin -0.20% |
| 4. Debt/Equity 1.34 |
| 5. Debt/Ebitda 7.78 |
| 6. ROIC - WACC (= -4.31)% |
| 7. RoE -4.77% |
| 8. Rev. Trend -64.31% |
| 9. EPS Trend -36.30% |
What is the price of BAX shares?
Over the past week, the price has changed by -6.84%, over one month by -24.69%, over three months by -27.72% and over the past year by -45.40%.
Is BAX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.1 | 38.2% |
| Analysts Target Price | 24.1 | 38.2% |
| ValueRay Target Price | 12.9 | -25.9% |
BAX Fundamental Data Overview November 17, 2025
P/E Forward = 7.874
P/S = 0.8721
P/B = 1.3112
P/EG = 34.2303
Beta = 0.611
Revenue TTM = 11.02b USD
EBIT TTM = 41.0m USD
EBITDA TTM = 1.03b USD
Long Term Debt = 8.75b USD (from longTermDebt, last quarter)
Short Term Debt = 755.0m USD (from shortTermDebt, last quarter)
Debt = 9.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.99b USD (from netDebt column, last quarter)
Enterprise Value = 17.60b USD (9.61b + Debt 9.71b - CCE 1.73b)
Interest Coverage Ratio = 0.13 (Ebit TTM 41.0m / Interest Expense TTM 311.0m)
FCF Yield = -0.13% (FCF TTM -22.0m / Enterprise Value 17.60b)
FCF Margin = -0.20% (FCF TTM -22.0m / Revenue TTM 11.02b)
Net Margin = -3.09% (Net Income TTM -341.0m / Revenue TTM 11.02b)
Gross Margin = 35.39% ((Revenue TTM 11.02b - Cost of Revenue TTM 7.12b) / Revenue TTM)
Gross Margin QoQ = 33.51% (prev 40.25%)
Tobins Q-Ratio = 0.84 (Enterprise Value 17.60b / Total Assets 21.07b)
Interest Expense / Debt = 0.60% (Interest Expense 58.0m / Debt 9.71b)
Taxrate = 142.1% (out of range, set to none) (172.0m / 121.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.84 (Total Current Assets 6.93b / Total Current Liabilities 3.77b)
Debt / Equity = 1.34 (Debt 9.71b / totalStockholderEquity, last quarter 7.24b)
Debt / EBITDA = 7.78 (Net Debt 7.99b / EBITDA 1.03b)
Debt / FCF = -363.0 (out of range, set to none) (Net Debt 7.99b / FCF TTM -22.0m)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.62% (Net Income -341.0m / Total Assets 21.07b)
RoE = -4.77% (Net Income TTM -341.0m / Total Stockholder Equity 7.15b)
RoCE = 0.26% (EBIT 41.0m / Capital Employed (Equity 7.15b + L.T.Debt 8.75b))
RoIC = 0.26% (EBIT 41.0m / (Assets 21.07b - Curr.Liab 3.77b - Cash 1.73b))
WACC = 4.57% (E(9.61b)/V(19.32b) * Re(9.19%) + (debt cost/tax rate unavailable))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
Fair Price DCF = unknown (Cash Flow -22.0m)
EPS Correlation: -36.30 | EPS CAGR: -8.46% | SUE: 0.81 | # QB: 0
Revenue Correlation: -64.31 | Revenue CAGR: -10.84% | SUE: -0.03 | # QB: 0
Additional Sources for BAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle